Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Oncolys Inks US$300 Million-Plus Pact for OBP-601; Potential for Neurodegenerative Diseases Eyed
Oncolys BioPharma said on June 15 that it will grant an exclusive worldwide license including sublicensing rights for its investigational nucleoside reverse transcriptase inhibitor OBP-601 (censavudine) to US upstart Transposon Therapeutics in a deal worth in excess of US$300 million.…
To read the full story
Related Article
- OBP-601 to Enter US PII for Neurodegenerative Diseases: Oncolys
August 17, 2021
BUSINESS
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026





